Author

Thomas Botton

InsermORCID 0000-0001-9079-7014Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Thomas Botton1 paper

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:metabolism & bioenergetics· 1 Approach:statistical model· 1

Frequent Co-Authors

Stéphane RocchiiD· 2 shared Adèle RivaultiD· 1 shared Alban Vigroux· 1 shared Ana Carolina Bastos Sant'Anna SilvaiD· 1 shared Anthony R. MartiniD· 1 shared Arnaud JacqueliD· 1 shared Arnaud PoterszmaniD· 1 shared Caroline RobertiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Stéphane RocchiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistryExperimental Hematology and OncologyPeer-reviewedMar 31, 2026

Dual targeting of GPX4 and TXNRD1 triggers eradication of AML cells through induction of apoptosis and ferroptosis

Cécile Favreau, Maxence Bourgoin, Coline Savy…·Guillaume Robert

The paper identifies two compounds that target GPX4 and TXNRD1 to induce apoptosis and ferroptosis in AML cells, effectively eradicating malignant cells while sparing normal hematopoietic cells.

DOI 10.1186/s40164-026-00766-4

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 31, 2025

MELK controls tumor metabolism to promote resistance to melanoma therapy

Ana Carolina Bastos Sant'Anna Silva, Patricia Abbe, Sophie Pagnotta…·Stéphane Rocchi

This study identifies MELK as a key driver of metabolic adaptation and therapy resistance in melanoma, showing that inhibiting MELK can sensitize resistant cells to immunotherapy.

DOI 10.64898/2025.12.31.697178

humanbulk RNA-seq

𝕏 PostBluesky